Affluent Medical SA

Paris Stock Exchange AFME.PA

Affluent Medical SA Capital Expenditure for the year ending December 31, 2023: USD -203.09 K

Affluent Medical SA Capital Expenditure is USD -203.09 K for the year ending December 31, 2023, a -30.01% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Affluent Medical SA Capital Expenditure for the year ending December 31, 2022 was USD -156.21 K, a 58.91% change year over year.
Affluent Medical SA Capital Expenditure for the year ending December 31, 2021 was USD -380.21 K, a -2.38% change year over year.
Affluent Medical SA Capital Expenditure for the year ending December 31, 2020 was USD -371.36 K, a -66.29% change year over year.
Affluent Medical SA Capital Expenditure for the year ending December 31, 2019 was USD -223.32 K.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Paris Stock Exchange: AFME.PA

Affluent Medical SA

CEO	Sebastien Ladet Ph.D.
IPO Date	June 14, 2021
Location	France
Headquarters	320, avenue Archimède
Employees	66
Sector	Health Care
Industries Medical Instruments Biotechnology Pharmaceuticals

Description

Affluent Medical SA develops minimally invasive medical devices for the treatment of heart and vascular diseases in France. It develops Kardiozis technology for the treatment of abdominal aortic aneurysm; Kalios and Epygon implants to treat mitral insufficiency; and Artus implant, an implantable electro-mechanical artificial sphincter for the treatment of severe urinary incontinence in women and men. The company was founded in 2011 and is based in Aix-en-Provence, France.

Key trends

Past 5 years